Galectin Therapeutics reported -7425000 in EBITDA for its fourth fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Bristol Myers Squibb BMY:US $ 5780M 8M
Gilead Sciences GILD:US $ 2585M 837M
Idera Pharmaceuticals IDRA:US $ -5.36M 1.18M
Intercept Pharmaceuticals ICPT:US $ -10.87M 0.98M
Regulus Therapeutics RGLS:US $ -7.14M 0.6M
Vital Therapies VTL:US $ -20.59M 0.82M
YTE INCY:US $ 276.8M 132.69M